NCT04888481View on ClinicalTrials.gov

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

600

Participants

Timeline

Start Date

February 15, 2022

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2028

Conditions

Neuroendocrine Tumors

Interventions

DRUG

68Ga-HA-DOTATATE

Tracer injection

Trial Locations (1)

T6G 2B7

RECRUITING

University of Alberta, Edmonton

All Listed Sponsors

lead

University of Alberta

OTHER